Please login to the form below
Avonex
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avonex was produced by Biogen Idec.
PMEA 2006: Winners in pictures
Avonex: How clear thinking and teamwork dramatically turned around the fortunes of a mature brand.
IPA Best of Health Awards
entry. agency. silver. Avonex - Shoe Box. Seven Stones. Idrolax - The Required Effect.
Biogen Q3 FY07 net profit falls nearly a quarter
MS drugs disappoint. Sales for Avonex (interferon beta-1a) increased 2.2 per cent to reach USD 454.9m.
Teva begins second Phase III trial of oral MS treatment
It will evaluate the safety, tolerability and effectiveness of laquinimod and produce risk-benefit data for laquinimod versus Avonex, an injectable treatment.
Multiple targets
Current treatments. Six MS disease-modifying drugs have been launched in the US and Europe since 1993: Avonex, Betaseron, Rebif, Copaxone, Novantrone and Tysabri.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- AZ secures capacity for one billion coronavirus vaccine doses
- UK’s new COVID-19 trial initiative fast-tracks BerGenBio’s bemcentinib
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- FDA clears phase 2 COVID-19 trial of ViralClear’s merimepodib
- Novartis to test canakinumab for COVID-19, as IL-6 trial disappoints
- Effectively communicating in a public health crisis
- DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
- Why are new medicinal products denied reimbursement in France?
- Lucid Group are shortlisted in three categories for Communiqué 2020
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
- This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
- Why are new medicinal products denied reimbursement in France?
- Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
Quick links
Infographics
